124 related articles for article (PubMed ID: 26905040)
1. Trimeric PEG-Conjugated Exendin-4 for the Treatment of Sepsis.
Lee W; Park EJ; Kwak S; Lee KC; Na DH; Bae JS
Biomacromolecules; 2016 Mar; 17(3):1160-9. PubMed ID: 26905040
[TBL] [Abstract][Full Text] [Related]
2. Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.
Kim TH; Jiang HH; Lim SM; Youn YS; Choi KY; Lee S; Chen X; Byun Y; Lee KC
Bioconjug Chem; 2012 Nov; 23(11):2214-20. PubMed ID: 23116483
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
[TBL] [Abstract][Full Text] [Related]
4. PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.
Sun Z; Tong G; Kim TH; Ma N; Niu G; Cao F; Chen X
Theranostics; 2015; 5(3):240-50. PubMed ID: 25553112
[TBL] [Abstract][Full Text] [Related]
5. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics.
Kim TH; Jiang HH; Lee S; Youn YS; Park CW; Byun Y; Chen X; Lee KC
Bioconjug Chem; 2011 Apr; 22(4):625-32. PubMed ID: 21401109
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.
Kim TH; Park CW; Kim HY; Chi MH; Lee SK; Song YM; Jiang HH; Lim SM; Youn YS; Lee KC
Biol Pharm Bull; 2012; 35(7):1076-83. PubMed ID: 22791155
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis.
Lee W; Ku SK; Park EJ; Na DH; Kim KM; Bae JS
Inflammation; 2014 Oct; 37(5):1876-88. PubMed ID: 24826914
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4 inhibits endothelial protein C receptor shedding in vitro and in vivo.
Ku SK; Han MS; Park EJ; Na DH; Bae JS
Pharmacol Res; 2014 Jun; 84():18-25. PubMed ID: 24769195
[TBL] [Abstract][Full Text] [Related]
9. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
Runge S; Schimmer S; Oschmann J; Schiødt CB; Knudsen SM; Jeppesen CB; Madsen K; Lau J; Thøgersen H; Rudolph R
Biochemistry; 2007 May; 46(19):5830-40. PubMed ID: 17444618
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.
Lee J; Lee C; Kim I; Moon HR; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Int J Pharm; 2012 Mar; 424(1-2):50-7. PubMed ID: 22226877
[TBL] [Abstract][Full Text] [Related]
11. A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action.
Kim I; Kim TH; Ma K; Park ES; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2011 Apr; 167(2-3):239-45. PubMed ID: 21329731
[TBL] [Abstract][Full Text] [Related]
12. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.
Talsania T; Anini Y; Siu S; Drucker DJ; Brubaker PL
Endocrinology; 2005 Sep; 146(9):3748-56. PubMed ID: 15932924
[TBL] [Abstract][Full Text] [Related]
13. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
Son S; Lim SM; Chae SY; Kim K; Park EJ; Lee KC; Na DH
Int J Pharm; 2015 Nov; 495(1):81-86. PubMed ID: 26325318
[TBL] [Abstract][Full Text] [Related]
14. The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice.
Liu R; Ma D; Li Y; Hu R; Peng Y; Wang Q
Acta Biochim Biophys Sin (Shanghai); 2014 Aug; 46(8):675-81. PubMed ID: 24951724
[TBL] [Abstract][Full Text] [Related]
15. Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats.
Malendowicz LK; Neri G; Nussdorfer GG; Nowak KW; Zyterska A; Ziolkowska A
Int J Mol Med; 2003 Oct; 12(4):593-6. PubMed ID: 12964040
[TBL] [Abstract][Full Text] [Related]
16. Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals.
Malendowicz LK; Nowak KW
Int J Mol Med; 2002 Sep; 10(3):327-31. PubMed ID: 12165809
[TBL] [Abstract][Full Text] [Related]
17. Uncovering CNS access of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet imaging.
Skovbjerg G; Roostalu U; Salinas CG; Skytte JL; Perens J; Clemmensen C; Elster L; Frich CK; Hansen HH; Hecksher-Sørensen J
Neuropharmacology; 2023 Nov; 238():109637. PubMed ID: 37391028
[TBL] [Abstract][Full Text] [Related]
18. Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system.
Lee C; Choi JS; Kim I; Byeon HJ; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Acta Biomater; 2014 Feb; 10(2):812-20. PubMed ID: 24140611
[TBL] [Abstract][Full Text] [Related]
19. Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment.
Liu Y; Wang G; Zhang H; Ma Y; Lang L; Jacobson O; Kiesewetter DO; Zhu L; Gao S; Ma Q; Chen X
Bioconjug Chem; 2016 Jan; 27(1):54-8. PubMed ID: 26641886
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
